Here, we report on a patient with characteristic features of Kleefstra syndrome carrying a novel splice-site mutation in EHMT1. The mutation was inherited from the mother who showed tissue-specific ...
Tango Therapeutics Inc. has patented histone-lysine N-methyltransferase EHMT1 (H3-K9-HMTase 5; GLP) and/or EHMT2 inhibitors reported to be useful for the treatment of cancer, sickle cell disease and β ...
- Dr. Steven Gray will lead research effort focused on potential therapy to replace the EHMT1 gene in patients with rare neurodevelopmental disorder ATLANTA, June 3, 2026 /PRNewswire/ -- IDefine – The ...
Kleefstra syndrome is a rare genetic disease caused by a mutation or deletion in one copy of a gene called EHMT1, which encodes for a protein called GLP. In the disorder, half the normal level of GLP ...
University of Chicago and IDefine partner to advance programmable RNA therapy for Kleefstra syndrome
CHICAGO, IL — The University of Chicago Department of Chemistry, in partnership with the advocacy organization IDefine – The Kleefstra Syndrome Foundation, is launching a targeted research program to ...
The University of Chicago Department of Chemistry, in partnership with the advocacy organization IDefine – The Kleefstra Syndrome Foundation, is launching a targeted research program to develop a new ...
A recent study published in Nature has reported two conserved epigenetic regulators as novel anti-aging targets. The research, by scientists from Dr. CAI Shiqing's Lab at the Center for Excellence in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results